Ascendis Pharma (Brazil) Buy Hold or Sell Recommendation
| A1SN34 Stock | BRL 53.35 1.65 3.00% |
Assuming the 90 days trading horizon and your complete indifference towards market risk, our recommendation regarding Ascendis Pharma AS is 'Cautious Hold'. Macroaxis provides Ascendis Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding A1SN34 positions.
Check out Ascendis Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Ascendis and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Ascendis |
Execute Ascendis Pharma Buy or Sell Advice
The Ascendis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Ascendis Pharma AS. Macroaxis does not own or have any residual interests in Ascendis Pharma AS or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Ascendis Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Ascendis Pharma Trading Alerts and Improvement Suggestions
| Ascendis Pharma AS had very high historical volatility over the last 90 days | |
| The company reported the revenue of 7.78 M. Net Loss for the year was (383.58 M) with profit before overhead, payroll, taxes, and interest of 4.25 M. | |
| Ascendis Pharma generates negative cash flow from operations |
Ascendis Pharma Returns Distribution Density
The distribution of Ascendis Pharma's historical returns is an attempt to chart the uncertainty of Ascendis Pharma's future price movements. The chart of the probability distribution of Ascendis Pharma daily returns describes the distribution of returns around its average expected value. We use Ascendis Pharma AS price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Ascendis Pharma returns is essential to provide solid investment advice for Ascendis Pharma.
| Mean Return | 0.40 | Value At Risk | -2.22 | Potential Upside | 1.76 | Standard Deviation | 3.24 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Ascendis Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Ascendis Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Ascendis Pharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Ascendis Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Ascendis stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.45 | |
β | Beta against Dow Jones | -0.47 | |
σ | Overall volatility | 3.21 | |
Ir | Information ratio | 0.09 |
Ascendis Pharma Volatility Alert
Ascendis Pharma AS exhibits very low volatility with skewness of 5.7 and kurtosis of 36.53. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Ascendis Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Ascendis Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Ascendis Pharma Fundamentals Vs Peers
Comparing Ascendis Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Ascendis Pharma's direct or indirect competition across all of the common fundamentals between Ascendis Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Ascendis Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Ascendis Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Ascendis Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Ascendis Pharma to competition |
| Fundamentals | Ascendis Pharma | Peer Average |
| Return On Equity | -0.67 | -0.31 |
| Return On Asset | -0.27 | -0.14 |
| Operating Margin | (15.89) % | (5.51) % |
| Current Valuation | 34.82 B | 16.62 B |
| Shares Outstanding | 57.03 M | 571.82 M |
| Price To Book | 0.90 X | 9.51 X |
| Price To Sales | 1,080 X | 11.42 X |
| Revenue | 7.78 M | 9.43 B |
| Gross Profit | 4.25 M | 27.38 B |
| EBITDA | (364.64 M) | 3.9 B |
| Net Income | (383.58 M) | 570.98 M |
| Book Value Per Share | 8.08 X | 1.93 K |
| Cash Flow From Operations | (417.65 M) | 971.22 M |
| Number Of Employees | 639 | 18.84 K |
| Beta | 0.47 | -0.15 |
| Market Capitalization | 34.39 B | 19.03 B |
| Total Asset | 1.08 B | 29.47 B |
| Net Asset | 1.08 B |
Ascendis Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Ascendis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 53.35 | |||
| Day Typical Price | 53.35 | |||
| Price Action Indicator | (0.82) | |||
| Period Momentum Indicator | (1.65) | |||
| Relative Strength Index | 89.21 |
About Ascendis Pharma Buy or Sell Advice
When is the right time to buy or sell Ascendis Pharma AS? Buying financial instruments such as Ascendis Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Ascendis Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Currency Funds Thematic Idea Now
Currency Funds
Funds or Etfs investing in a single currency or combination of currencies from different countries in order to replicate respective foreign exchange markets. The Currency Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Currency Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Ascendis Stock
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Ascendis Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.